• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of optimized methods for measurement of platelet activation using flow cytometry

Research Project

Project/Area Number 11470515
Research Category

Grant-in-Aid for Scientific Research (B).

Allocation TypeSingle-year Grants
Section一般
Research Field Laboratory medicine
Research InstitutionHOKKAIDO UNIVERSITY

Principal Investigator

MATSUNO Kazuhiko  Hokkaido Univ., College of Medical Technology, Professor, 医療技術短期大学部, 教授 (70102332)

Co-Investigator(Kenkyū-buntansha) CHIBA Hitoshi  Hokkaido Univ., Medical hospital School of Med., Lec., 医学部・附属病院, 講師 (70197622)
Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥5,900,000 (Direct Cost: ¥5,900,000)
Fiscal Year 2000: ¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1999: ¥4,000,000 (Direct Cost: ¥4,000,000)
Keywordsplatelets / flow cytometry / CD62P / CD63 / PAC-1 / CD36 / oxidized LDL / 活性化 / β-トロンボグロブリン
Research Abstract

Platelets play key roles in the pathophysiology of thrombosis. It is important to evaluate platelet activation in vivo in order to predict the possibility of thrombosis. The purpose of this study is to establish optimized methods to monitor the activation status of circulating platelets in patients. We investigated the sensitivity of various monoclonal antibodies (MoAbs) against activation-dependent antigen (CD62P, CD63, PAC-1, CD107a, CD107b, SPAN12, WADE15) firstly. MoAbs against CD62P, CD63, PAC-1 was the most sensitive for the detection of platelet activation in vitro. Secondarily we studied the extent of ex vivo platelet activation after blood collection. A significant reduction in basal CD62P and CD63 expression was obtained when blood was fixed immediately after blood collection. However, it was necessary to incubate whole blood anticogulated with EDTA or Na citrate with anti-PAC-1 MoAb before fixation with paraformaldehyde concerning PAC-1 assay. We compared the difference of 4 methods to measure the activation of circulating platelets. No significant difference was observed in 4 methods when whole blood was fixed with paraformaldehyde right after blood collection. But it is necessary to collect blood with anticoagulant mixture (EDTA + Na citrate + adenosine + theophyllin) when whole blood is left as it is for 0.5〜1 hour. The expression of CD62P, CD63 and PAC-1 on unstimulated platelets was significantly higher in patients with dialysis than that in normal controls. ADP-stimulated expression of CD62P and CD63 on platelets was significantly higher in patients with dialysis and nephritic syndrome than that in normal controls. Oxidized-LDL-stimulated expression of CD62P on platelets was significantly lower in CD36 negative population than in CD36 positive population.

Report

(3 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] Yanai H.: "Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol."Am J Med Gen. 93. 299-304 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yanai H.: "Type I CD36 deficiency in humans is not associated with insulin resistance syndrome."Thromb Haemost. 83・5. 786 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yanai H.: "Phenotype-genotype correlation in CD36 deficiency Type I and II."Thromb Haemost. 84・3. 436-441 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hidekatsu Yanai, et al: "Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol."Am J Med Gen. 93. 299-304 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hidekatsu Yanai, et al.: "Type I CD36 deficiency in humans is not associated with insulin resistance syndrome."Thromb Haemost. 83(5). 786 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hidekatsu Yanai, et al.: "Phenotype-genotype correlation in CD36 deficiency Type I and II."Thromb Haemost. 84(3). 436-441 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yanai H,: "Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol."Am J Med Gen. 93. 299-304 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Yanai H: "Type I CD36 deficiency in humans is not associated with insulin resistance syndrome."Thromb Haemast. 83・5. 786 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Yanai H.: "Phenotype-genotype correlation in CD36 deficiency Type I and II."Thromb Haemost. 84・3. 436-441 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 松野一彦: "血小板の分子マーカー"Vita. 17・3. 69-73 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hidekatsu Yanai: "Type I CD36 deficiency in humans is not associated with insulin resistance syndrome"Thrombosis and Haemostasis. 83(3) (in press). (2000)

    • Related Report
      1999 Annual Research Report
  • [Publications] Hidekatsu Yanai: "Human CD36 deficiency is associated with elevation in low-density Lipoprotein-Cholesterol"American Journal of Medical Genetics. (in press). (2000)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi